In MS lesions, the prolonged presence of fibronectin as a consequence of a decreased ability to clear fibronectin by the lack of fibronectin (aggregate) clearing matrix metalloproteinases, such as MMP744, may increase the chance of encountering a TLR3 agonist as a double hit. The gene discussed is FN1; the disease is myeloid sarcoma.